209 related articles for article (PubMed ID: 28597167)
21. Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group.
Park KM; Yoo KH; Kim SK; Lee JW; Chung NG; Ju HY; Koo HH; Lyu CJ; Han SM; Han JW; Choi JY; Hong KT; Kang HJ; Shin HY; Im HJ; Koh KN; Kim H; Kook H; Baek HJ; Kim BR; Yang EJ; Lim JY; Park ES; Choi EJ; Park SK; Lee JM; Shim YJ; Kim JY; Park JK; Kong SG; Choi YB; Cho B; Lim YT
Cancer Res Treat; 2022 Jan; 54(1):269-276. PubMed ID: 33887821
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
[TBL] [Abstract][Full Text] [Related]
23. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F
Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658
[TBL] [Abstract][Full Text] [Related]
24. Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States.
Rashidi A; Riley M; Goldin TA; Sayedian F; Bayerl MG; Aguilera NS; Vos JA; Goudar RK; Fisher SI
Leuk Res; 2014 Sep; 38(9):1036-40. PubMed ID: 25035073
[TBL] [Abstract][Full Text] [Related]
25. Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).
Hassan IB; Zaabi MRA; Alam A; Hashim MJ; Tallman MS; Kristensen J
Int J Hematol; 2017 Jul; 106(1):90-98. PubMed ID: 28293819
[TBL] [Abstract][Full Text] [Related]
26. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
27. Early Mortality in Children and Adolescents with Acute Promyelocytic Leukemia: Experience of the Boldrini Children's Center.
de Azevedo AC; Matsuda E; Cervellini JY; Prandi LR; Omae C; Jotta PY; Pereira RM; Brandalise SR
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e641-e646. PubMed ID: 31613846
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
30. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.
Micol JB; Raffoux E; Boissel N; Lengliné E; Canet E; Daniel MT; Labarthe Ad; Maarek O; Cassinat B; Adès L; Baruchel A; Degos L; Azoulay E; Dombret H
Eur J Cancer; 2014 Apr; 50(6):1159-68. PubMed ID: 24440088
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Zhang Y; Hou W; Cao F; Lu M; Yang H; Tian X; Wang Y; Hou J; Fu J; Li H; Zhou J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):485-492. PubMed ID: 31686248
[TBL] [Abstract][Full Text] [Related]
32. Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.
Wen J; Xu F; Zhou Q; Shi L; Liu Y; Yue J; Zhang Y; Liang X
BMC Cancer; 2023 Jan; 23(1):27. PubMed ID: 36611025
[TBL] [Abstract][Full Text] [Related]
33. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
[TBL] [Abstract][Full Text] [Related]
34. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.
de Botton S; Chevret S; Coiteux V; Dombret H; Sanz M; San Miguel J; Caillot D; Vekhoff A; Gardembas M; Stamatoulas A; Conde E; Guerci A; Gardin C; Fey M; Cony Makhoul D; Reman O; de la Serna J; Lefrere F; Chomienne C; Degos L; Fenaux P;
Leukemia; 2003 Feb; 17(2):339-42. PubMed ID: 12592333
[TBL] [Abstract][Full Text] [Related]
35. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005).
Zhang Y; Wang L; Zhang R; Qi P; Xie J; Shi H; Lin W; Wu Y; Yu J; Fan J; Feng G; Zheng H; Wu M
Pediatr Hematol Oncol; 2019 Oct; 36(7):399-409. PubMed ID: 31530209
[TBL] [Abstract][Full Text] [Related]
37. A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemia.
García-Casado Z; Cervera J; Valencia A; Pajuelo JC; Mena-Duran AV; Barragán E; Bolufer P; Sanz MA
Cancer Genet Cytogenet; 2006 Jul; 168(1):73-6. PubMed ID: 16772124
[TBL] [Abstract][Full Text] [Related]
38. [Clinical and laboratory features of patients with CD34(+) acute promyelocytic leukemia].
Liang JY; Wu DP; Liu YJ; Ma QF; Xue YQ; Zhu MQ; Chen ZX
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):196-8. PubMed ID: 19615259
[TBL] [Abstract][Full Text] [Related]
39. Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Kutny MA; Gregory J; Feusner JH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):69-78. PubMed ID: 24907019
[TBL] [Abstract][Full Text] [Related]
40. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
